BioLine Rx Ltd is a clinical-stage biopharmaceutical development company with a strategic focus on oncology. Its development and commercialization pipeline consist of two clinical-stage therapeutic candidates - Motixafortide (BL-8040), a novel peptide for the treatment of solid tumors, hematological malignancies and stem cell mobilization, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, it has an off- strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions.BioLine Rx Ltd is a clinical stage biopharmaceutical development company engaged in identifying, in-licensing & developing therapeutic compounds. Its pipeline product include BL-8040, BL-9020, BL-5010, BL-1230, and AGI-134.